Gordian Capital Singapore Pte Ltd Invests $268,000 in Merus (NASDAQ:MRUS)

Gordian Capital Singapore Pte Ltd bought a new position in Merus (NASDAQ:MRUS) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,530 shares of the biotechnology company’s stock, valued at approximately $268,000.

Several other large investors also recently added to or reduced their stakes in MRUS. Allspring Global Investments Holdings LLC bought a new stake in Merus during the first quarter worth approximately $72,000. SG Americas Securities LLC bought a new stake in Merus during the first quarter worth approximately $108,000. Sierra Summit Advisors LLC bought a new stake in Merus during the fourth quarter worth approximately $221,000. Farallon Capital Management LLC bought a new stake in Merus during the second quarter worth approximately $237,000. Finally, ProShare Advisors LLC bought a new stake in Merus during the second quarter worth approximately $242,000. 96.14% of the stock is owned by institutional investors.

Merus Stock Performance

Shares of NASDAQ MRUS opened at $50.10 on Wednesday. The firm has a market capitalization of $2.94 billion, a price-to-earnings ratio of -18.19 and a beta of 1.12. The stock has a 50 day moving average price of $51.18 and a 200 day moving average price of $50.04. Merus has a 52-week low of $19.81 and a 52-week high of $61.61.

Merus (NASDAQ:MRUS) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.05). The firm had revenue of $7.33 million during the quarter, compared to analysts’ expectations of $9.64 million. Merus had a negative net margin of 476.41% and a negative return on equity of 36.33%. Analysts forecast that Merus will post -3.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on MRUS. Guggenheim boosted their price objective on Merus from $93.00 to $111.00 and gave the stock a “buy” rating in a research note on Tuesday. Bank of America restated a “buy” rating and set a $76.00 target price on shares of Merus in a research report on Tuesday, June 25th. Truist Financial boosted their target price on Merus from $69.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. BMO Capital Markets boosted their target price on Merus from $84.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday, June 4th. Finally, Stifel Nicolaus boosted their target price on Merus from $90.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, June 17th. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Merus currently has a consensus rating of “Buy” and a consensus target price of $82.00.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.